{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:11:49Z","timestamp":1780528309473,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejim.2022.04.014","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T16:52:46Z","timestamp":1650300766000},"page":"27-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual antiplatelet treatment for minor acute ischemic stroke and high-risk transient ischemic attack: have we reached the limit of antithrombotic management?"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-3797","authenticated-orcid":false,"given":"Georgios","family":"Tsivgoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristeidis H.","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2022.04.014_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2022.03.017","article-title":"P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis","volume":"100","author":"Pomero","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.04.014_bib0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejim.2022.04.014_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.04.014_bib0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.04.014_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.04.014_bib0006","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.2022.0300","article-title":"Time to Retire the Concept of Transient Ischemic Attack","volume":"327","author":"Easton","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2022.04.014_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/WCO.0000000000000878","article-title":"The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy","volume":"34","author":"Kargiotis","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ejim.2022.04.014_bib0008","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","article-title":"Five-year risk of stroke after TIA or minor ischemic stroke","volume":"378","author":"Amarenco","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.04.014_bib0009","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejim.2022.04.014_bib0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/STROKEAHA.119.028409","article-title":"CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke","volume":"51","author":"Hankey","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2022.04.014_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2017.03.010","article-title":"High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis","volume":"376","author":"Fiolaki","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ejim.2022.04.014_bib0012","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"377","key":"10.1016\/j.ejim.2022.04.014_bib0013","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"2017","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2022.04.014_bib0014","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS Trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2022.04.014_bib0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.119.040180","article-title":"Novel drug targets for ischemic stroke identified through mendelian randomization analysis of the blood proteome","volume":"140","author":"Chong","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2022.04.014_bib0016","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamaneurol.2020.2494","article-title":"New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention","volume":"77","author":"Katsanos","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:36:32Z","timestamp":1760607392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":16,"alternative-id":["S0953620522001558"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.04.014","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual antiplatelet treatment for minor acute ischemic stroke and high-risk transient ischemic attack: have we reached the limit of antithrombotic management?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.03.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}